Research peptide stores sell these compounds as research chemicals, not as medicines. Some of the same ingredients are in approved medicines, but an approval covers one maker's finished product. Nothing listed on PeptidesGrid is one of the approved products named below.
This page gives the regulatory status of all 46 peptides on the site as of Sep 25, 2026. It is a status check only. It is not medical advice and not advice to use anything.
How we checked
On Sep 25, 2026 we searched Drugs@FDA, the European Medicines Agency (EMA) medicines list and Health Canada's Drug Product Database for every ingredient. For products still in trials we read the companies' own releases. For approvals in other countries we checked company filings and Vidal, a Russian drug reference that lists each product's registration. We did not search every country's register.
Status of all 46 peptides
| Peptide | Status on Sep 25, 2026 |
|---|---|
| Approved in the US, EU or Canada | |
| Tirzepatide | Mounjaro and Zepbound, from Eli Lilly. Approved by the FDA (Mounjaro, 2022; Zepbound, 2023), the EMA (Mounjaro, 2022) and Health Canada (both products). |
| Semaglutide | Ozempic, Wegovy and Rybelsus, from Novo Nordisk. Approved by the FDA, the EMA and Health Canada. The EMA also approved Kayshild (Novo Nordisk) in March 2026. Health Canada approved generic semaglutide from Dr. Reddy's (announced April 28, 2026), then from Apotex (including Sevmia), Aspen and Sandoz. |
| Tesamorelin | Egrifta, from Theratechnologies. FDA, 2010. The EU application was withdrawn in 2012. Health Canada's listings were cancelled in 2022 and 2023. |
| SS-31 | Elamipretide, sold as Forzinity by Stealth BioTherapeutics, now Mighty Therapeutics. FDA accelerated approval, September 19, 2025. Not approved in the EU or Canada. |
| PT-141 | Bremelanotide, sold as Vyleesi by Cosette Pharmaceuticals. FDA, 2019. Not approved in the EU or Canada. |
| Oxytocin | Pitocin, from Par Health, is FDA approved. Other makers' oxytocin injections are approved in the US and Canada. |
| Melanotan I | Afamelanotide, sold as a 16 mg implant (Scenesse) by Clinuvel. Approved by the EMA (2014), the FDA (2019) and Health Canada (2026). Research vendors sell the peptide in vials, which is not the approved product. |
| Approved elsewhere, not by the FDA, EMA or Health Canada | |
| Mazdutide | Xinermei, from Innovent Biologics under a license from Eli Lilly. China's NMPA approved it on June 27, 2025, with a second approval on September 19, 2025. |
| Thymosin Alpha-1 | Thymalfasin, sold as Zadaxin by SciClone Pharmaceuticals. SciClone's annual report for 2004 lists approvals in over 30 countries, mainly in Asia, the Middle East and Latin America. |
| Selank | Selank, from Peptogen, is registered as a medicine in Russia. |
| Semax | Semax, from Peptogen, is registered as a medicine in Russia. |
| DSIP | Deltaran, from the KOMKON research center, contains DSIP. It has been registered in Russia since 2016. |
| GHRP-2 | Pralmorelin, sold in Japan as GHRP Kaken 100 (Kaken Pharmaceutical) for diagnosing growth hormone deficiency. Approved in Japan in 2004. |
| VIP | Aviptadil, combined with phentolamine as Invicorp (Evolan Pharma), is authorised nationally in Germany, Denmark, Finland, France, Norway, Sweden and Northern Ireland. Not approved by the FDA, the EMA or Health Canada. |
| In clinical development | |
| Retatrutide | Eli Lilly, phase 3. On July 23, 2026 Lilly said it plans to apply for US approval in Q1 2027. |
| Cagrilintide | Novo Nordisk, phase 3. On September 16, 2025 Novo said it would move it into its own phase 3 program, RENEW. |
| CagriSema | Novo Nordisk applied for FDA approval on December 18, 2025. Its Q2 2026 report expects the US decision in Q4 2026. |
| Survodutide | Phase 3, run by Boehringer Ingelheim, which licensed it from Zealand Pharma. Results from SYNCHRONIZE-2 are due at the EASD meeting, September 28 to October 2, 2026. |
| Not approved anywhere we could find | |
| BPC-157, TB-500, KPV, MOTS-c, Epitalon | No approved product found. An FDA advisory committee voted on compounding them in July 2026. That is not an approval; see below. |
| GHK-Cu, Ipamorelin, CJC-1295 no DAC, CJC-1295 DAC, HGH Frag 176-191, AOD-9604, Kisspeptin-10 | No approved product found. |
| NAD+ | Not a peptide. No approved NAD+ product found. |
| Melanotan II | No approved product found. A different peptide, afamelanotide, is approved in the EU as Scenesse (Clinuvel). |
| Sermorelin | Once approved in the US as Geref (EMD Serono). The maker stopped selling it, and the FDA withdrew the approvals in 2009. |
| BPC-157 + TB-500, GLOW, KLOW, CJC-1295 + Ipamorelin | Vendor blends. No approved product contains these mixes. |
| LL-37, ARA-290, Pinealon, FOXO4-DRI, GHRP-6, Hexarelin | No approved product found. |
| IGF-1 LR3 | No approved product found. Mecasermin (Increlex), which is unmodified IGF-1, is approved; it is a different molecule. |
| Glutathione | Not approved as a medicine on its own. Its oxidised form is only a minor ingredient of approved eye irrigation solutions. |
| SNAP-8 | Acetyl octapeptide-3, listed as a cosmetic ingredient in the EU. Not approved as a medicine. |
What "approved" means here
- An approval covers one product from one maker. The regulator reviews that maker's formula, dose form, factory and label. It does not cover the same ingredient made or sold by anyone else. A research vial of tirzepatide is not Mounjaro or Zepbound.
- Generics need their own approval. Health Canada approved each generic semaglutide product separately. In the US, Apotex's generic semaglutide has only a tentative approval, dated April 7, 2026, and Drugs@FDA lists no marketing status for it.
- Compounding votes are not approvals. On July 23 and 24, 2026, an FDA advisory committee reviewed seven peptides for the list of substances pharmacies may use to compound. It voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, and against emideltide (DSIP). The pharmacists' group NCPA notes that the votes "are not binding on the FDA" and that pharmacies cannot compound them until a final rule is in place. Even a final listing would not approve any product.
- Approvals can end. Sermorelin's US approvals were withdrawn in 2009, and tesamorelin's Canadian listings were cancelled.
- "EU" here means an EU-wide authorization from the EMA. Single EU countries can also approve medicines on their own; this page does not cover those.
Re-check dates: the FDA decision on CagriSema, which Novo expects in Q4 2026; survodutide's SYNCHRONIZE-2 results at EASD, September 28 to October 2, 2026, and any filing that follows; any final FDA rule on the compounding list; and Lilly's planned US filing for retatrutide in Q1 2027.
Status checked Sep 25, 2026 against Drugs@FDA, the EMA medicines list, Health Canada's Drug Product Database, Vidal and company releases. Approvals change, so check the regulator's own record. Last reviewed Sep 25, 2026.